<DOC>
	<DOCNO>NCT00379483</DOCNO>
	<brief_summary>A 1-year randomized Phase IIa core trial follow prolongation 5 9 month conduct investigate efficacy safety deferasirox patient age â‰¥ 18 year transfusion-dependent iron overload . The objective extension study ass long-term safety deferasirox provide treatment patient transfusional iron overload .</brief_summary>
	<brief_title>Extension Study Iron Chelation Therapy With Deferasirox Patients With Transfusional Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Patients transfusional iron overload successfully complete one year chelation treatment deferasirox trial foodeffect substudy consider investigator eligible continue chelation therapy deferasirox Pregnant breast feeding patient Patients consider investigator potentially unreliable and/or history noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Transfusional iron overload</keyword>
	<keyword>Deferasirox</keyword>
</DOC>